Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 12, 2017

Primary Completion Date

May 12, 2022

Study Completion Date

May 12, 2022

Conditions
Mild Alzheimer's Disease
Interventions
DRUG

IONIS MAPTRx

IONIS MAPTRx injections.

OTHER

Placebo

Artificial CSF injections.

Trial Locations (13)

53127

Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn

Unknown

Montreal Neurological Hospital, Montreal

Clinical Research Services Turku CRST, Turku

St Josef Hospital, Bochum

MVZ Mittweida Gbr, Mittweida

Universittsklinikum Ulm, Ulm

Minnesmottagningen, Mölndal

Karolinska University Hospital Huddinge, Stockholm

Royal Liverpool University Hospital, Liverpool

University College London Hospitals NHS Foundation Trust, London

Sheffield Institute for Translational Neuroscience (SITraN), Sheffield

1081 HV

VU University Medical Center, Amsterdam

9713 AG

QPS Netherlands BV, Groningen

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY